Showing 5791-5800 of 7373 results for "".
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Fourth Generation Retinoid Shows Promise in Acne Trialshttps://practicaldermatology.com/news/fourth-generation-retinoid-shows-promise-in-acne-trials/2457699/New research reveals that trifarotene, a fourth-generation retinoid with potent and selective activity against only one particular retinoic acid receptor, may have an improved efficacy and safety profile compared with less selective r
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- Jury Still Out on Environmental Effects of Chemical Sunscreenshttps://practicaldermatology.com/news/jury-still-out-on-environmental-effects-of-chemical-sunscreens/2457705/In the wake of Hawaiian legislation banning the sale and distribution of sunscreens containing oxybenzone and octinoxate because they may contribute to coral bleaching, new research reviews the available data on chemical ultraviolet filters found in U.S. sunscreens. The
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- UVBioTek Launches POLY Go Portable LED Light Therapyhttps://practicaldermatology.com/news/uvbiotek-launches-poly-go-portable-led-light-therapy/2457714/UVBioTek has launched a new line of hand-held LED therapy products that support their newest brand, POLY LED Light Therapy. The mobile hand-held products, named “POLY Go”, use multiple wavelengths that are clinically proven to cater to those with acne, fine-
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Xact Nabs Best of Hot Topics at ASAPS 2018https://practicaldermatology.com/news/xact-nabs-best-of-hot-topics-at-asaps-2018/2457727/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (ASAPS) meeting in New York. Xact technology is a minimally invasive face and neck lifting suturing d
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i